ACIP unanimously recommends Dengvaxia use, with same caveats as FDA label; Chinese 3D printing company with rheumatoid arthritis drug completes Series B financing
ACIP has recommended use of Sanofi’s dengue vaccine by a unanimous vote, but there’s a catch.
With the 14-0 vote Thursday, ACIP said the shots should be given to children aged 9 to 16 only if they’ve had a previous infection and live in areas where dengue is endemic. In the US, that’s largely a reference to Puerto Rico and other island territories. The vote comes two years after the FDA approved the shot.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
